Oxymetazoline Hydrochloride and Poliovirus vaccine, inactivated Injection

• Generic Name: oxymetazoline ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Visine LR, Visine Long Lasting, Ocuclear

Self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies.

As effective as other topical vasoconstrictors.

Labeled and has been used for self-medication for temporary relief of nasal congestion associated with sinusitis; however, efficacy data are lacking and/or controversial. In October 2005, FDA issued final rule to remove this indication from labeling of OTC nasal decongestants. Compliance date for preparations with annual sales <$25,000 is October 11, 2007; compliance date for all other preparations is April 11, 2007.

Self-medication for temporary relief of ocular redness due to minor irritation.

Has been used for self-medication for symptomatic prevention of otitic barotrauma (aerotitis [barotitis] media); however, no more effective than placebo.

• Generic Name: poliovirus vaccine, inactivated
• Dosage Forms: n.a.
• Other Brand Names: Ipol

Poliovirus vaccine is an active immunizing agent used to prevent poliomyelitis (polio). It works by causing your body to produce its own protection (antibodies) against the virus that causes polio.

There are two types of polio vaccine that are given by injection, poliovirus vaccine inactivated (IPV) and poliovirus vaccine inactivated enhanced potency (eIPV). In the U.S. and Canada, the type of vaccine that is given by injection is eIPV. The type of vaccine that is given by mouth is called poliovirus vaccine live oral (OPV).

Polio is a very serious infection that causes paralysis of the muscles, including the muscles that enable you to walk and breathe. A polio infection may leave a person unable to breathe without the help of an iron lung, unable to walk without leg braces, or confined to a wheelchair. There is no cure for polio.

Immunization against polio is recommended for all infants from 6 to 12 weeks of age, all children, all adolescents up to 18 years of age, and certain adults who are at greater risk for exposure to polioviruses than the general population, including:

• Persons traveling to areas or countries where polio is uncontrolled, whether or not they have been vaccinated against polio in the past.
• Persons who live in areas where polio infection still occurs.
• Adults who have not been vaccinated or who have not had the complete series of vaccinations against polio and who live in households with children who are to be given the oral polio vaccine (OPV).
• Employees in day-care centers and group homes for children, such as orphanages.
• Employees in medical facilities, such as hospitals and doctors' offices.
• Laboratory workers handling samples that may contain polio viruses.

Immunization against polio is not recommended for infants younger than 6 weeks of age, because antibodies they received from their mothers before birth may interfere with the effectiveness of the vaccine. Infants who were immunized against polio before 6 weeks of age should receive the complete polio immunization series.

This vaccine is to be administered only by or under the supervision of your doctor or other health care professional.